Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;12(11):3025-3033.e6.
doi: 10.1016/j.jaip.2024.07.028. Epub 2024 Aug 6.

A Skin Testing Strategy for Non-IgE-Mediated Reactions Associated With Vancomycin

Siyan Lyu  1 , Eric T Oliver  2 , Melanie C Dispenza  2 , Kristin L Chichester  2 , Jennifer Hoffman  3 , Donald W MacGlashan  2 , N Franklin Adkinson  2 , Elizabeth J Phillips  4 , Santiago Alvarez-Arango  5
Affiliations

A Skin Testing Strategy for Non-IgE-Mediated Reactions Associated With Vancomycin

Siyan Lyu et al. J Allergy Clin Immunol Pract. 2024 Nov.

Abstract

Background: Vancomycin infusion reaction (VIR), reportedly mediated through Mas-Related G Protein-Coupled Receptor-X2, is the primary vancomycin-induced immediate drug reaction. Clinically, distinguishing the underlying drug-induced immediate drug reaction mechanisms is crucial for future treatment strategies, including drug restriction, re-administration, and pretreatment considerations. However, the lack of validated diagnostic tests makes this challenging, often leading to unnecessary drug restriction.

Objective: To determine whether intradermal tests (IDTs) and, separately, the basophil activation test (BAT) differentiate VIR from vancomycin-tolerant subjects.

Methods: This was a cross-sectional study of vancomycin-exposed adults with and without a history of VIR. Data on demographics, allergy-related comorbidities, history of vancomycin exposures, and VIR characteristics were collected. IDT with vancomycin was performed. IDT dose-response EC50, IDT-related local symptoms, and BAT results were compared between groups.

Results: A total of 11 VIR and 10 vancomycin-tolerant subjects were enrolled. The most reported VIR symptoms were pruritus (82%), flushing (82%), hives (46%), angioedema (27%), and dyspnea (19%). The IDT dose-response mean EC50 was 328 μg/mL (95% CI, 296-367) in the VIR versus 1166 μg/mL (95% CI, 1029-1379) in the tolerant group (P < .0001). All VIR subjects reported IDT-related local pruritus compared with 60% of tolerant subjects (P = .0185). The %CD63+ basophils were consistently less than 2%, without significant differences between groups (P < .54).

Conclusions: Variations in skin test methodologies could help identify other immediate drug reaction mechanisms beyond IgE. This skin test protocol holds the potential for identifying VIR, particularly in cases where patients have received multiple drugs while BAT is insufficient. Future studies will validate and delineate its predictive value, assessing the risk of VIR.

Keywords: Basophil activation test; Dose-response curve; Drug allergy; Immediate drug reaction; MRGPRX2; MRGPRX2 ligands; Non-IgE-mediated immediate drug reaction; Skin test; Vancomycin infusion reaction.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors declare that the research was conducted without any commercial or financial relationships that could potentially create a conflict of interest.

References

    1. Navinés-Ferrer A, Serrano-Candelas E, Lafuente A, Muñoz-Cano R, Martín M, Gastaminza G. MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia. Scientific reports. 2018;8(1):11628. - PMC - PubMed
    1. Foer D, Wien M, Karlson EW, Song W, Boyce JA, Brennan PJ. Patient Characteristics Associated With Reactions to Mrgprx2-Activating Drugs in an Electronic Health Record–Linked Biobank. The Journal of Allergy and Clinical Immunology: In Practice. 2023;11(2):492–9. e2. - PMC - PubMed
    1. Alvarez-Arango S, Ogunwole SM, Sequist TD, Burk CM, Blumenthal KG. Vancomycin infusion reaction—moving beyond “red man syndrome”. The New England journal of medicine. 2021;384(14):1283. - PMC - PubMed
    1. Alvarez-Arango S, Yerneni S, Tang O, Zhou L, Mancini CM, Blackley SV, et al. Vancomycin hypersensitivity reactions documented in electronic health records. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(2):906–12. - PMC - PubMed
    1. Azimi E, Reddy VB, Lerner EA. MRGPRX2, atopic dermatitis, and red man syndrome. Itch. 2017;2(1):e5. - PMC - PubMed

LinkOut - more resources